Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07656688

Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease

Clinical trial aims to determine the optimal dosing regimen by evaluating the efficacy and safety of HUC1-394 across different dosing frequencies in patients with moderate to severe dry eye disease.

Recruiting

Interested in participating?

Request Info

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Yonsei University Health System, Severance Hospital

Seoul, South Korea

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged ≥ 19 years at the time of screening
  • Trial participants who have experienced at least one of the following dry eye disease symptoms for at least 3 months prior to the time of screening
  • Trial participants who meet all of the following criteria in at least one eye (left or right) at the time of screening and randomization:

TCSS (NEI grading) ≥ 4 / Non-anesthetic Schirmer test result > 0 mm and ≤ 10 mm/5 min / TBUT < 7 seconds

  • OSDI score ≥ 23 at the time of screening
  • Trial participants who have provided voluntary written informed consent after receiving a full explanation and understanding of the clinical trial

Exclusion criteria

  • Trial participants with clinically significant ophthalmic diseases that may confound the interpretation of clinical trial results
  • Trial participants with blepharospasm, entropion, ectropion, or abnormalities of the eyelashes
  • Trial participants with any active ophthalmic disease that may affect the ocular surface, such as active allergy, anterior uveitis, and Stevens-Johnson syndrome
  • Trial participants with a history of corneal transplantation or neurotrophic keratitis
  • Trial participants with autoimmune diseases or immunodeficiency disorders
  • Pregnant or lactating women, or women of childbearing potential and men of reproductive potential who plan to conceive during the clinical trial or are unwilling to use an appropriate method of contraception
  • Trial participants who have participated in another clinical trial and received an investigational product or used an investigational medical device within 30 days prior to the time of screening
  • Trial participants who are deemed ineligible for participation by the investigator for any other reason in the clinical trial

Treatment and study plan

HUC1-394

Drug

ophthalmic solution. Participants will instill 1 drop in each eye

Placebo

Drug

ophthalmic solution. Participants will instill 1 drop in each eye

Primary outcomes

  1. Change from Baseline in Total Corneal Staining Score (TCSS) Using the National Eye Institute (NEI) Scale

    Time frame: Week 12

    NEI scale (range 0-15; higher scores indicate a worse outcome)

Study contacts

Contact information is provided by the study sponsor or research team.

study manager

CONTACT

[email protected]

07074926091

Sponsors and collaborators

Lead sponsor

Huons Co., Ltd.

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Clinical Study to Evaluate the Efficacy and Safety of HUC1-394 in Participant With Dry Eye Disease

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jun 18, 2026
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.